Advertisement

Annals of Hematology

, Volume 98, Issue 10, pp 2425–2426 | Cite as

Haploidentical stem cell transplantation with post-transplant cyclophosphamide in leukocyte adhesion deficiency type 1: a case report

  • Vipin KhandelwalEmail author
  • Sanjeev Kumar Sharma
  • Divya Doval
  • Meet Kumar
  • Dharma Choudhary
Letter to the Editor
  • 41 Downloads

Dear Editor,

Leukocyte adhesion deficiency type 1 (LAD-1) is a rare autosomal recessive primary immunodeficiency disease (PID) that results from defective expression of the beta-2 integrin, CD18, on immune cells and results in impaired leukocyte adhesion, egression, and migration [1]. Hematopoietic stem cell transplant (HSCT) is the only known curative approach for LAD-1 treatment [2]. In the absence of a matched related donor (MRD) and matched unrelated donor (MUD), haploidentical HSCT using T cell replete graft with post-transplant cyclophosphamide (PT-CY) is an emerging option for patients with both malignant and benign hematological conditions [3, 4]. We report here the successful haploidentical transplantation using T cell replete graft and PT-CY in a patient with LAD-1.

A 15-month-old female child was diagnosed with LAD-1 at the age of 3 months. She had poor weight gain and frequent admissions for sepsis. Her umbilical cord had separated at the 4 weeks of age. There was no family...

Notes

Compliance with ethical standards

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Conflict of interest

None.

Informed consent

Was obtained from the patient’s parents in this study.

References

  1. 1.
    Movahedi M, Entezari N, Pourpak Z, Mamishi S, Chavoshzadeh Z, Gharagozlou M, Mir-Saeeid-Ghazi B, Fazlollahi MR, Zandieh F, Bemanian MH, Farhoudi A (2007) Clinical and laboratory findings in Iranian patients with leukocyte adhesion deficiency (study of 15 cases). J Clin Immunol 27:302–307CrossRefGoogle Scholar
  2. 2.
    Qasim W, Cavazzana-Calvo M, Davies EG, Davis J, Duval M, Eames G, Farinha N, Filopovich A, Fischer A, Friedrich W, Gennery A, Heilmann C, Landais P, Horwitz M, Porta F, Sedlacek P, Seger R, Slatten M, Teague L, Eapen M, Veys P (2009) Allogeneic hematopoietic stem-cell transplantation for leukocyte adhesion deficiency. Pediatrics 123:836–840CrossRefGoogle Scholar
  3. 3.
    Bashey A, Solomon SR (2014) T-cell replete haploidentical donor transplantation using post-transplant CY: an emerging standard-of-care option for patients who lack an HLA-identical sibling donor. Bone Marrow Transplant 49:999–1008CrossRefGoogle Scholar
  4. 4.
    Raiola AM, Dominietto A, di Grazia C, Lamparelli T, Gualandi F, Ibatici A, et al (2014) Unmanipulated haploidentical transplants compared with other alternative donors and matched sibling grafts. Biol Blood Marrow Transplant 20(10):1573–1579Google Scholar
  5. 5.
    Chiesa R, Veys P (2012) Reduced-intensity conditioning for allogeneic stem cell transplant in primary immune deficiencies. Expert Rev Clin Immunol 8(3):255–266 quiz 267CrossRefGoogle Scholar
  6. 6.
    Almarza Novoa E, Kasbekar S, Thrasher AJ, Kohn DB, Sevilla J, Nguyen T, Schwartz JD, Bueren JA (2018) Leukocyte adhesion deficiency-I: a comprehensive review of all published cases. J Allergy Clin Immunol Pract 6(4):1418–1420CrossRefGoogle Scholar
  7. 7.
    Neven B, Diana JS, Castelle M, Magnani A, et al (2019) Haploidentical hematopoietic stem cell transplantation with post transplant cyclophosphamide for primary immunodeficiencies and inherited disorders in children. Biol Blood Marrow Transplant 25(7):1363–1373Google Scholar
  8. 8.
    Chiesa R, Gilmour K, Qasim W, Adams S, Worth AJJ, Zhan H, Montiel-Equihua CA, Derniame S, Cale C, Rao K, Hiwarkar P, Hough R, Saudemont A, Fahrenkrog CS, Goulden N, Amrolia PJ, Veys P (2012) Omission of in vivo T-cell depletion promotes rapid expansion of naive CD41 cord blood lymphocytes and restores adaptive immunity within 2 months after unrelated cord blood transplant. Br J Haematol 156(5):656–666CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  • Vipin Khandelwal
    • 1
    Email author
  • Sanjeev Kumar Sharma
    • 1
  • Divya Doval
    • 1
  • Meet Kumar
    • 1
  • Dharma Choudhary
    • 1
  1. 1.Department of Hemato-oncology and Bone marrow transplantationBLK Superspeciality HospitalNew DelhiIndia

Personalised recommendations